UK IBD investigators, will your site participate in this fully funded non-inferiority trial?
Can you recruit one patient a month?...
PROFILE is currently open in 33 centres around the UK (with 7 more to come) and aims to recruit 400 participants over the next 2 years
The MRC Stratified Medicine application entitled ‘Minimising Mortality from Alcoholic Hepatitis’ will commence in April 2018 and will last for 5 years.
The UKCTG service has traditionally provided public and professional users with information on what it means to participate in a clinical trial.
Dr Matthias Zilbauer, of the University of Cambridge, has been awarded £100k for a project aiming to find a way to predict how a child’s condition is likely to progress if they are diagnosed with IBD – whether the child’s symptoms are likely to be mild and require minimal treatment, or more severe, needing more intensive treatment
PRECISION-Panc is an ambitious programme of research that seeks to uncover the molecular profile of individual patients with pancreatic cancer.
Despite huge progress in the outpatient management of ulcerative colitis, there are still around 2,500 admissions for acute severe UC in the UK every year.
The research team were successful in securing £358,183 funding from the HTA for an add on study
Joint collaborations between members of the British Society of Gastrointestinal and Abdominal Radiology (BSGAR) and the BSG have led to recent grant success from the NIHR
Planning to deliver a study in the NHS?
The Health Research Authority (HRA) has published a new brief leaflet setting out high level information about the HRA Approval process.
A phase 2, multi-centre, international therapeutic trial has been approved in the UK for patients with Wilson's disease.
The UK Clinical Research Collaboration (UKCRC) Registered CTU Network is a network of academic clinical trials units (CTUs) that have been assessed by an international panel of experts in clinical trials research.
The world’s largest ever clinical trial looking at whether taking aspirin every day stops some of the most common cancers coming back launched on 22 October 2015.
Inclusion of patients receiving Biosimilar Infliximab - Remsima™ & Inflectra™
HCV Research UK is a national cohort of over 11,000 patients enrolled between 2012 and 2014 from 60 centres within the UK with evidence of hepatitis C virus infection.